References
- Torrance N, Smith BH, Bennett MI, et al. The epidemiology of chronic pain of predominately neuropathic origin. Results from a general population survey. J Pain 2006;7:281-9
- Jensen M, Chodroff M, Dworkin R. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 2007;68:1178-82
- Lister S, Gabriel Z, McEwan P, et al. Linking UK patients’ self-reported pain with healthcare resource use and quality of life. Presented at the British Pain Society Annual Scientific Meeting, Manchester, April 2010
- Dworkin RH, Corbin AE, Young JP, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo controlled trial. Neurology 2003;60:1274-83
- Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005;115:254-63
- Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004;110:628-38
- Annemans L, Caekelbergh K, Morlion B, et al. A cost-utility analysis of pregabalin in the management of peripheral neuropathic pain. Acta Clin Belg 2008;63:170-8
- Rodriguez MJ, Diaz S, Vera-Llonch M, et al. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. Curr Med Res Opin 2007;23:2585-96
- Tarride JE, Gordon A, Vera-Llonch M, et al. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective. Clin Ther 2006;28:1922-34
- Smith KJ, Roberts MS. Sequential medication strategies for postherpetic neuralgia: a cost-effectiveness analysis. J Pain 2007;8:396-404
- National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal (reference N0515). 2004. http://www.nice.org.uk/aboutnice/howwework/devnicetech/technologyappraisalprocessguides/guide_to_the_methods_of_technology_appraisal_reference_n0515.jsp. Accessed 30 June 2011
- Lyrica Capsules - Summary of Product Characteristics (SPC) - electronic Medicines Compendium (eMC). Datapharm Communications Ltd. http://www.medicines.org.uk/emc/medicine/14651. Accessed 30 June 2011
- Patient UK. Neuropathic pain. http://www.patient.co.uk/health/Neuropathic-Pain.htm. Accessed 30 June 2011
- Stacey BR, Dworkin RH, Murphy K, et al. Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial. Pain Med 2008;9:1202-8
- Douglas E, Forbes RD, Smith SC, et al. An audit of pregabalin for refractory neuropathic pain. Poster presented at British Pain Society, Liverpool, April 2007
- Allen S. Pregabalin – is it any better than gabapentin? Poster presented at 2005 World Congress of Pain, Sydney, Australia
- Freynhagen R, Grond S, Schuepfer G, et al. Efficacy and safety of pregabalin in treatment refractory patients with various neuropathic pain entities in clinical routine. Int J Clin Pract 2007;61:1989-96
- Hanu-Cernat, Harrison GR, Blaney LP, et al. Pregabalin, the first cases. Poster presented at 2005 IASP, Sydney, Australia
- Toth C. The utility of pregabalin in neuropathic pain patients – degree of benefit in responders and non-responders to gabapentin. Eur J Pain 2007;11(1 Suppl):S150
- Dolan P. Modeling valuations for EuroQol Health States. Medical Care 1997;35:1095-1108.
- Netten A. & Curtis L. Unit costs of health and social care. Personal Social Services Research Unit (PSSRU) 2004/05. http://www.pssru.ac.uk/uc/uc.htm. Accessed December 18, 2008
- Salisbury C, Hollinghurst S, Montgomery A, et al. The impact of co-located NHS walk-in centres on emergency departments. Emerg Med J 2007;24:265-9
- National audit office. NHS direct in England. http://www.nao.org.uk/publications/nao_reports/01-02/0102505.pdf. 2009. Accessed 7 July 2010
- Joint Formulary Committee. British National Formulary (BNF). 57 edn. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2009
- NHS Prescription Services. Electronic drug tariff. http://www.ppa.org.uk/ppa/edt_intro.htm. 2009. Accessed 7 July 2010
- Van Seventer R, Feister HA, Young JP, et al. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomised trial. Curr Med Res Opin 2006;22:375-84